Recent treatment advances in Hodgkin Lymphoma: a concise review

Arulogun, Suzanne, Hertzberg, Mark and Gandhi, Maher K. (2016) Recent treatment advances in Hodgkin Lymphoma: a concise review. Internal Medicine Journal, 46 12: 1364-1369. doi:10.1111/imj.13051

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ396233_OA.pdf Full text (open access) application/pdf 1.10MB 0

Author Arulogun, Suzanne
Hertzberg, Mark
Gandhi, Maher K.
Title Recent treatment advances in Hodgkin Lymphoma: a concise review
Journal name Internal Medicine Journal   Check publisher's open access policy
ISSN 1444-0903
Publication date 2016-03-01
Year available 2016
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1111/imj.13051
Open Access Status File (Author Post-print)
Volume 46
Issue 12
Start page 1364
End page 1369
Total pages 11
Place of publication Richmond, Australia
Publisher Wiley-Blackwell Publishing Asia
Language eng
Formatted abstract
The majority of patients with Hodgkin Lymphoma enjoy durable remissions following front-line treatment. This typically involves combination chemotherapy with or without radiotherapy. A significant minority of patients experience relapsed/refractory disease, of whom only approximately half can be ‘salvaged’ with conventional second-line treatments. Until recently, for those patients either failing or who are not fit for salvage, there have been few curative alternatives. Furthermore, there is a significant risk of delayed treatment complications to conventional therapies, including secondary malignancies and cardiac disease. However, novel targeted therapies are producing excellent results in clinical trials. They provide additional treatment options for those with relapsing/refractory disease; they may also have potential in front-line therapy. The anti-CD30 antibody brentuximab vedotin has been tested as monotherapy and in combination in a variety of clinical settings, including in relapsed/refractory patients and as consolidative therapy following standard second-line therapy. Nivolumab and Pembrolizumab, currently used in other malignancies that are also known to utilise the programmed death pathway for survival, have shown outstanding results when used as single agents in heavily pre-treated (including brentuximab vedotin refractory) patients. Individualising and adapting a patient's treatment course, whether augmenting or rationalising therapy, based on an interim PET/CT response is an important strategy currently under exploration to minimise toxicity while maximising response. Further work is needed to explore clinical and biological factors associated with improved outcomes. Knowledge of these factors combined with the movement of novel therapies into the front-line setting will enable individualised therapy to enhance clinical responses and minimize toxicities.
Keyword Hodgkin Lymphoma
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: HERDC Pre-Audit
UQ Diamantina Institute Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 2 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 13 Jul 2016, 04:58:59 EST by Maher Gandhi on behalf of UQ Diamantina Institute